Advancing a new class of immunotherapies w/ targeted, fully-human polyclonal antibodies for C. diff, seasonal influenza, & Type 1 diabetes without human donors.
Location: United States, South Dakota, Sioux Falls
Investors 1
| Date | Name | Website |
| 22.09.2024 | T1D Fund | t1dfund.or... |
Mentions in press and media 1
| Date | Title | Description |
| 31.03.2023 | SAB Biotherapeutics Provides Company Update for Full Year 2022 | /EIN News/ -- SIOUX FALLS, S.D., March 31, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency,... |